(redirected from autologous transplant)
Also found in: Dictionary, Medical, Encyclopedia.
Related to autologous transplant: allogeneic transplant, syngeneic transplant
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for autograft

tissue that is taken from one site and grafted to another site on the same person


Related Words

References in periodicals archive ?
Till now, we were doing only autologous transplants which involved the usage of the patient's own stem cells.
Today, "some centers perform autologous transplant outpatient, but our patients are generally discharged the day after transplant," Parran says, "while those undergoing unrelated allogeneic transplants generally stay around a month.
Also, no researchers had adequately compared protracted consolidation/maintenance chemotherapy--the mainstay of treatment for acute lymphocytic leukemia (ALL)--with autologous transplant to determine efficacy.
Holding back tears she said: "The autologous transplant will only prolong Wesley's life a little more than six months.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled([R]), propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.
DLBCL is an aggressive type of non-Hodgkin lymphoma for which the primary treatment options are front-line chemotherapy and, in selected patients, autologous transplant.
An autologous transplant uses the patient's own bone marrow to serve as a graft.
About 60% of patients with multiple myeloma achieved complete remission when a conventional autologous transplant was combined with a nonmyeloablative allogenic transplant, Dr.
The issue of high dose chemotherapy and autologous transplant is a good example.
Ligand's Captisol-enabled melphalan program, which has been granted Orphan Drug status by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma, is a new IV formulation of melphalan (currently sold as Alkeran([R]) for Injection) that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting.
An autologous transplant uses the patient's own remaining healthy blood-forming cells that are collected and used later for transplant.
Mozobil, in combination with G-CSF, is designed to release hematopoietic stem cells from the bone marrow into the bloodstream where they can be collected, making it more likely for patients with certain types of cancers to proceed to autologous transplant.
Elderly patients who cannot receive an autologous transplant receive combinations of chemotherapies in first line treatment (melphalan, cyclosphosphamide, corticoids) associated with Thalidomide[R] or Velcade[R].
Most of the multiple myeloma (ML) patients age 70 or older are offered less effective non-transplant treatments that in the long run may be more toxic and expensive than a single autologous transplant.
In an autologous transplant, the patient receives his or her own stem cells and is usually performed so that higher doses of chemotherapy can be given to treat blood cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, and amyloidosis.
Full browser ?